Business Context and Reporting Period
Company: SELLAS Life Sciences Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2023
Reporting Period: Event date December 11, 2023
Business Context: The Company entered into a Second Amendment to Sublease regarding its principal executive offices located at 7 Times Square, New York, NY.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a material definitive agreement regarding lease terms.
| Lease Term Extension | Details |
|---|---|
| New Expiration Date | September 30, 2025 |
| Previous Expiration Date | December 30, 2024 |
| Rent (Dec 31, 2024) | $0.00 |
| Rent (Jan 1, 2025 - Sep 30, 2025) | $635,250.00 per annum ($52,937.50 per month) |
| Additional Costs | Operating expenses applicable to the Premises |
Material Changes
The primary material change is the extension of the sublease term for the Company's New York headquarters by approximately nine months. The agreement modifies the rent structure to include a rent-free period for the final day of 2024, followed by a defined annual rent rate for the extension period in 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing provides no forward-looking guidance, outlook, or management commentary beyond the terms of the lease amendment.
Risks and Contingencies: The filing does not disclose new risks or contingencies. The Company remains obligated to pay operating expenses during the extension term.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the total cash impact of the lease extension ($635,250 annualized for the partial year of 2025).
- Confirm the specific operating expense obligations associated with the Premises.
- Review the full text of the Second Amendment to Sublease (Exhibit 10.1) for any covenants or termination rights not summarized here.
- Assess the impact of the extended lease term on the Company's future cash burn rate and runway.